Top Injectable Manufacturer in Lebanon – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 22 hours ago
- 8 min read
Last Updated: August 23, 2026
TL;DR: Lebanon imports roughly 70% of its medicines and registers every one of them at the Ministry of Public Health, where a Drug Registration Technical Committee reviews files built in CTD structure and a named Lebanese agent must appear in Module 1. Price is set as part of the marketing authorisation against a basket of seven European and seven Middle Eastern reference countries plus the country of origin, and imported generics are capped at up to 30% below the originator price – a wider corridor than the 15% allowed to locally made generics. Total pharmaceutical imports reached US$737 million in 2024, of which India supplied about US$29 million. Farbe Firma Pvt Ltd manufactures sterile injectables on ISO Class 5 aseptic lines in a WHO-GMP certified facility in Gujarat, India, and supports Lebanese importers on dossier, GMP certification and legalisation.
Key Takeaways
Price is decided with the licence, not after it. Lebanon sets the price during the marketing authorisation process, taking the relevant figure from a basket of seven European and seven Middle Eastern reference countries, the price in the country of origin, and – for a generic – the originator's price. An imported generic may be priced up to 30% below the originator, while a locally manufactured generic is limited to 15% below. Where several generic brands compete, firms routinely price well under the cap. Build your commercial case around that corridor before you file, because the number that comes out of registration is the number you live with.
Lebanon is not an Apostille country. Lebanon is not a party to the 1961 Hague Apostille Convention, so a GMP certificate, company profile or free-sale document issued in India cannot be apostilled for use in Beirut. Plan for the full consular legalisation chain – notarisation and India's Ministry of External Affairs, then the Lebanese diplomatic mission – and confirm the exact document list with your Lebanese agent, because legalisation lead time is the item most often left out of a first-time exporter's schedule.
You need a named Lebanese agent from the start. MoPH's dossier requirements ask explicitly for the name and address of the agent in Lebanon in Module 1, alongside the product's marketing status in the country of origin. This is not a formality you can add later: the import market is concentrated, with around eight major importers and distributors accounting for roughly 85% of total pharmaceutical imports in 2023, and several multinationals now contract those same houses for regulatory affairs as well as distribution.
Local manufacture reshapes what is worth exporting. Lebanon has twelve domestic manufacturers, three of which make parenteral solutions, and the local share of the prescription market by value reached 34% in 2022 after subsidy policy was changed to stop favouring imports. An imported generic cannot be subsidised where the same active substance is manufactured in Lebanon. The realistic export opportunity is therefore in molecules and presentations local plants do not cover – which, for sterile injectables, is most of the hospital and oncology-support basket.
Introduction: Why Lebanon Demands a Premium Injectable Manufacturer in Lebanon
Lebanon is a market of about 5.85 million people that imports roughly 70% of the medicines it consumes, and it has spent the last several years rebuilding a pharmaceutical supply system under extraordinary fiscal pressure. Pharmaceutical imports under Customs Chapter 30 reached US$737 million in 2024, up from US$621 million in 2023 and US$552 million in 2022, against local production of around US$150 million and exports of US$47 million. The 2024 supplier table was led by the United States at 11.8%, Germany at 11.66%, France at 8.95% and Switzerland at 7.19%. India supplied about US$29 million under the same chapter – close to 4%, a mid-tier position with real room to grow.
The pressure on that system is not abstract. Medication costs rose by more than 1,100% between 2018 and 2022, central bank subsidies that once financed roughly US$200 million of medicine imports a year were progressively withdrawn between 2019 and 2022 until only 129 of some 5,500 registered drugs remained partially subsidised, and the Order of Pharmacists has estimated the grey and black market at 25–30% of total consumption. In January 2025 the World Health Organization issued an alert covering falsified durvalumab identified in Lebanon, Türkiye and Armenia. In a market under that kind of strain, a supplier whose quality documentation is beyond argument is not a luxury – it is the whole proposition.
What Sets a World-Class Injectable Manufacturer in Lebanon Apart
Start with the registration mechanics. Every pharmaceutical product sold in Lebanon, imported or locally made, must be registered with the Ministry of Public Health; MoPH states plainly that any importation or distribution not submitted to its control is illegal and liable to confiscation. Files pass through a Drug Registration Technical Committee, and MoPH delivers its pharmaceutical policy through the Quality Assurance of Pharmaceutical Products Program launched in 2012. Pharmacy practice is governed by Law 367/1994, with Article 43 as amended by Law 91/2010 covering the pharmacist's substitution right, while registration procedure runs under Decree 571. A Lebanese Drug Agency has been created in law but is not yet operative pending its implementation decrees, so MoPH remains the counterparty in practice.
Then look at the file itself. MoPH works in CTD structure, and its published requirements go as far as a Module 6 pharmacovigilance plan covering track and trace, recall and adverse reaction reporting for biosimilars. Module 1 asks for the Lebanese agent's name and address and the product's marketing status in the country of origin. The registration manual calls for a company profile, a plant profile, a GMP certificate, Module 3 quality data, methods of analysis, stability data, certificates of analysis and batch release, mock-ups, and bioequivalence data for generics, with annexed forms listing reference countries and reference laboratories. MoPH aligns its decisions with reference agencies such as the European Medicines Agency and the US FDA. Lebanon is not a PIC/S member and has no national medicines quality control laboratory, and most of the process remains paper-based – all of which means the quality of what you hand over on paper carries more weight, not less.
Quality Systems Behind Every Sterile Injectable
Farbe Firma fills sterile injectables on ISO Class 5 aseptic lines inside a WHO-GMP certified facility in Gujarat, India. Sterility assurance is engineered rather than inspected in: terminal sterilisation or aseptic processing chosen on the product's own characteristics, media fill validation, continuous environmental and personnel monitoring, container closure integrity testing and a documented contamination control strategy. Analytical release runs on HPLC and GC for assay and related substances, LAL for bacterial endotoxins, Karl Fischer where water content is critical, and compendial sterility testing, with specifications set against USP, BP, IP or EP as the destination monograph requires.
Stability is generated to ICH Q1A(R2) with photostability under ICH Q1B on conditions appropriate to a Mediterranean climate rather than borrowed from a temperate dataset, which matters in a country where cold-chain and storage capacity have been rebuilt under strain – the MoPH central drug warehouse at Karantina was expanded from 3,000 to 8,000 cubic metres with nine cold rooms added after the port explosion. Documentation is assembled in CTD structure to match what MoPH expects, and the certificates that carry the most weight in a Lebanese file – the GMP certificate and the certificate of analysis – are prepared with legalisation in mind from the outset rather than chased after a deficiency letter.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Lebanon for Global Buyers
The commercial logic of this market rewards generics that can prove themselves. Physicians are legally required to prescribe by international non-proprietary name, pharmacists may substitute brands of identical composition with the patient's consent under Law 91/2010, and the MedLeb app lets patients compare the prices of competing brands directly – which has put sustained downward pressure on high-volume generic prices. Generics were about 24% of the market in 2022 and the local manufacturers' share has climbed steadily since. An imported sterile injectable wins here on documented equivalence, reliable supply and a defensible price inside the 30% corridor, not on brand history.
Public and donor-funded demand is a distinct channel with its own rhythm. The MoPH central drug warehouse at Karantina distributes acute and catastrophic medicines and vaccines to more than a thousand centres. The Essential Drugs Program delivers quality generic chronic-disease medicines through around 500 primary care facilities, with the YMCA handling management, fundraising and warehousing and WHO conducting the procurement; beneficiaries grew from 80,000 before the crisis to 240,000 by June 2023. MediTrack, the two-dimensional barcode track-and-trace system launched in 2023, covers 280 subsidised medicines linked to individual patients and MoPH intends to extend it across the prescription market. A supplier who can meet serialisation-grade packaging and artwork requirements is positioned for that extension rather than surprised by it.
Farbe Firma Pvt Ltd works as both manufacturer and CDMO, which suits a market served through a concentrated group of importers with institutional, donor and private demand running in parallel. We support English and Arabic artwork and inserts, flexible batch sizes so an importer is not obliged to take tender-scale quantities for a private-channel product, dossier compilation in CTD structure, and the GMP certificate, plant profile, stability and analytical documentation a MoPH file requires – prepared with the consular legalisation chain accounted for. Contract development and manufacturing, own-label supply and technology transfer are all available on the same quality system.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Who regulates medicine registration in Lebanon?
The Ministry of Public Health (MoPH). Every pharmaceutical product, imported or locally manufactured, must be registered with MoPH, and applications are reviewed by a Drug Registration Technical Committee. MoPH's pharmaceutical policy runs through its Quality Assurance of Pharmaceutical Products Program, launched in 2012. A Lebanese Drug Agency has been established in law but will only become effective once its implementation decrees are issued, so MoPH remains the operative authority.
How is the price of an imported generic injectable set in Lebanon?
Price is set as part of the marketing authorisation process. MoPH compares the price in a basket of seven European and seven Middle Eastern reference countries, the price in the country of origin, and – for a generic – the originator's price in Lebanon. An imported generic may be priced up to 30% below the originator, while a locally manufactured generic is capped at 15% below. MoPH publishes a public price list in Lebanese pounds that is reissued as the exchange rate moves, with several editions issued during 2026.
Does Lebanon accept an Apostille on Indian GMP certificates?
No. Lebanon is not a party to the 1961 Hague Apostille Convention, so documents issued in India cannot be apostilled for Lebanese use. They require the full consular legalisation chain instead – notarisation, then India's Ministry of External Affairs, then the Lebanese diplomatic mission. Confirm the precise document list and sequence with your Lebanese agent before you begin, since legalisation adds real calendar time to a first submission.
Do I need a Lebanese agent or distributor to register and sell a product?
In practice, yes. MoPH's dossier requires the name and address of the agent in Lebanon, and foreign exporters generally work through a Lebanese agent or distributor who clears and distributes the goods domestically. The market is concentrated: around eight major importers and distributors handled roughly 85% of Lebanon's total pharmaceutical imports in 2023, and several international companies now contract those houses for regulatory affairs as well as for sales and distribution.
What makes Farbe Firma a suitable injectable manufacturer for the Lebanese market?
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. We compile CTD dossiers to the structure MoPH expects, generate ICH Q1A(R2) and Q1B stability data, supply GMP certificates, plant and company profiles, certificates of analysis and bioequivalence documentation prepared with consular legalisation in mind, and support English and Arabic artwork. Contact director@farbefirma.org to discuss a specific molecule, tender or own-label programme.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments